(Total Views: 419)
Posted On: 08/14/2019 6:23:34 AM
Post# of 156437
525 and 700mg still going strong, 94% with 525 mg and 85% with 700 mg
The last update was 3 months ago, May 6th, and we just dropped 1% in 525 as more patients are getting to the finish line.
From May: New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab
https://www.cytodyn.com/newsroom/press-releas...ab-pro-140
I also think the last statement is important, probably the reason for the face to face meeting to finalize the mono protocol.
Recent data suggests that the receptor occupancy test being fine-tuned by Dr. Bruce Patterson may effectively identify potential responders to monotherapy at the time of screening, thereby potentially raising the success rate in the monotherapy program,” Dr. Pourhassan concluded.
Here is the protocol Pr, I believe they will move away from 700mg at beginning to random assignment at 10 weeks, and use this test to determine the dose at the beginning.
https://www.cytodyn.com/newsroom/press-releas...onotherapy
In this study, patients will receive a combination of existing retroviral regimen and leronlimab 700 mg SC for four weeks (the overlap phase) before shifting to weekly leronlimab 700mg monotherapy for 10 weeks (the monotherapy induction phase). Subsequently, patients will be randomized 1:1 to leronlimab 525mg (Group A) or leronlimab 700mg (Group
for a 36-week monotherapy maintenance phase.
The last update was 3 months ago, May 6th, and we just dropped 1% in 525 as more patients are getting to the finish line.
From May: New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab
https://www.cytodyn.com/newsroom/press-releas...ab-pro-140
I also think the last statement is important, probably the reason for the face to face meeting to finalize the mono protocol.
Recent data suggests that the receptor occupancy test being fine-tuned by Dr. Bruce Patterson may effectively identify potential responders to monotherapy at the time of screening, thereby potentially raising the success rate in the monotherapy program,” Dr. Pourhassan concluded.
Here is the protocol Pr, I believe they will move away from 700mg at beginning to random assignment at 10 weeks, and use this test to determine the dose at the beginning.
https://www.cytodyn.com/newsroom/press-releas...onotherapy
In this study, patients will receive a combination of existing retroviral regimen and leronlimab 700 mg SC for four weeks (the overlap phase) before shifting to weekly leronlimab 700mg monotherapy for 10 weeks (the monotherapy induction phase). Subsequently, patients will be randomized 1:1 to leronlimab 525mg (Group A) or leronlimab 700mg (Group
for a 36-week monotherapy maintenance phase. 
(1)
(0)
